AKT1 and acute myeloid leukemia: Recent in vitro studies found that suppression of RAC with a RAC inhibitor (EHT-1864) could increase autophagy, apoptosis, cell cycle, modulation of p53 factor and inhibit the PI3K/AKT/mTOR signaling pathway in AML cell lines (38).